{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:13:47Z","timestamp":1759796027197,"version":"build-2065373602"},"reference-count":44,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T00:00:00Z","timestamp":1756252800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["headachejournal.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Headache"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>The objective of this study was to investigate the pharmacokinetics of rimegepant in participants with mild, moderate, or severe renal impairment compared to healthy adults with normal renal function.<\/jats:p><\/jats:sec><jats:sec><jats:title>Background<\/jats:title><jats:p>Rimegepant is a calcitonin gene\u2010related peptide receptor antagonist approved in the United States for treatment of acute and preventive treatment of migraine.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this Phase 1, open\u2010label, four\u2010group, pharmacokinetic study, 36 participants were grouped by degree of renal impairment according to estimated glomerular filtration rate (eGFR): normal; mild (60\u201389\u2009mL\/min\/1.73\u2009m<jats:sup>2<\/jats:sup>); moderate (30\u201359\u2009mL\/min\/1.73\u2009m<jats:sup>2<\/jats:sup>); and severe (&lt;30\u2009mL\/min\/1.73\u2009m<jats:sup>2<\/jats:sup>). Participants received a single 75\u2010mg oral rimegepant tablet to determine total and unbound plasma rimegepant concentrations using both matched and pooled control analysis. The study enrollment period began on October 17, 2017, and concluded on March 27, 2018.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>For mild, moderate, and severe renal impairment groups, respectively, compared with matched control groups, total geometric least\u2010square mean ratios (90% confidence intervals) were 1.06 (0.75\u20131.52), 1.40 (0.97\u20132.02), and 1.04 (0.70\u20131.57) for area under the concentration\u2013time curve from time zero to infinity (AUC<jats:sub>0\u2013inf<\/jats:sub>) and 1.20 (0.75\u20131.92), 0.76 (0.42\u20131.37), and 0.90 (0.50\u20131.62) for maximum observed concentration (<jats:italic>C<\/jats:italic><jats:sub>max<\/jats:sub>). Geometric mean ratios of unbound AUC<jats:sub>0\u2013inf<\/jats:sub> were 1.22 (0.82\u20131.82), 1.84 (1.30\u20132.61), and 2.57 (1.86\u20133.56) in the mild, moderate, and severe renal impairment groups, respectively, using the pooled control group analysis. Relationships for eGFR versus total plasma concentrations and pharmacokinetic parameters showed no significant trends; however, there was a statistically significant (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05) relationship showing greater unbound rimegepant AUC<jats:sub>0\u2013inf<\/jats:sub> and <jats:italic>C<\/jats:italic><jats:sub>max<\/jats:sub> in participants with lower eGFR.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Among participants with mild, moderate, or severe renal impairment, a \u226440% increase in total rimegepant exposure was observed following single\u2010dose 75\u2010mg administration. Unbound rimegepant AUC<jats:sub>0\u2013inf<\/jats:sub> exposure increased 1.8\u2010 and 2.6\u2010fold in participants with moderate and severe renal impairment, respectively. The pharmacokinetic results from this study and safety data from other clinical studies were used to support rimegepant dosing recommendations in patients with renal impairment. Rimegepant has not been studied in patients with end\u2010stage renal disease or in patients on dialysis and should be avoided in those populations.<\/jats:p><\/jats:sec>","DOI":"10.1111\/head.15041","type":"journal-article","created":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T07:04:14Z","timestamp":1756278254000},"page":"1381-1393","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The influence of renal impairment on the pharmacokinetics of rimegepant: Results of a phase 1, open\u2010label, single\u2010dose, parallel\u2010group study"],"prefix":"10.1111","volume":"65","author":[{"given":"Rajinder","family":"Bhardwaj","sequence":"first","affiliation":[{"name":"Certara USA  Princeton New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beth","family":"Morris","sequence":"additional","affiliation":[{"name":"Biohaven Pharmaceuticals, Inc.  New Haven Connecticut USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Bertz","sequence":"additional","affiliation":[{"name":"Biohaven Pharmaceuticals, Inc.  New Haven Connecticut USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyle","family":"Matschke","sequence":"additional","affiliation":[{"name":"Pfizer Inc.  Collegeville Pennsylvania USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Croop","sequence":"additional","affiliation":[{"name":"Biohaven Pharmaceuticals, Inc.  New Haven Connecticut USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Liu","sequence":"additional","affiliation":[{"name":"Pfizer Inc.  Groton Connecticut USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,8,27]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102417738202"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13281"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2007.00752.x"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-018-0617-4"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/bs.pbr.2020.06.019"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13529"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/164_2018_201"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2019.1618830"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107528"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2021.1895749"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1358\/dot.2020.56.12.3211624"},{"volume-title":"Rimegepant Prescribing Information","year":"2021","author":"FDA","key":"e_1_2_13_13_1"},{"volume-title":"Vydura Prescribing Information","year":"2022","author":"EMA","key":"e_1_2_13_14_1"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1177\/03331024231179131"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14512"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14836"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.1244"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.1337"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13727"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1177\/03331024231219505"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1177\/25158163211007922"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1089\/bfm.2021.0250"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.1230"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.1352"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.1088"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2005.05.010"},{"key":"e_1_2_13_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2008.59"},{"key":"e_1_2_13_29_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102413500727"},{"key":"e_1_2_13_30_1","doi-asserted-by":"publisher","DOI":"10.2147\/jpr.S453806"},{"key":"e_1_2_13_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1811090"},{"key":"e_1_2_13_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(19)31606-x"},{"key":"e_1_2_13_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(20)32544-7"},{"key":"e_1_2_13_34_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-130-6-199903160-00002"},{"issue":"1","key":"e_1_2_13_35_1","first-page":"26","article-title":"Sheehan suicidality tracking scale (Sheehan\u2010STS): preliminary results from a multicenter clinical trial in generalized anxiety disorder","volume":"6","author":"Coric V","year":"2009","journal-title":"Psychiatry"},{"key":"e_1_2_13_36_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g3596"},{"volume-title":"Pharmacokinetics in Patients with Impaired Renal Function\u2014Study Design, Data Analysis, and Impact on Dosing Guidance for Industry","year":"2024","author":"FDA","key":"e_1_2_13_37_1"},{"volume-title":"StatPearls","year":"2025","author":"Kyriakopoulos C","key":"e_1_2_13_38_1"},{"key":"e_1_2_13_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(23)00126-6"},{"key":"e_1_2_13_40_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12121180"},{"key":"e_1_2_13_41_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-198400091-00003"},{"key":"e_1_2_13_42_1","doi-asserted-by":"publisher","DOI":"10.1177\/03331024241232944"},{"key":"e_1_2_13_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11910-018-0845-3"},{"key":"e_1_2_13_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(16)30293-9"},{"key":"e_1_2_13_45_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.70051"}],"container-title":["Headache: The Journal of Head and Face Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/head.15041","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T05:44:18Z","timestamp":1759729458000},"score":1,"resource":{"primary":{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/10.1111\/head.15041"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,27]]},"references-count":44,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.1111\/head.15041"],"URL":"https:\/\/doi.org\/10.1111\/head.15041","archive":["Portico"],"relation":{},"ISSN":["0017-8748","1526-4610"],"issn-type":[{"type":"print","value":"0017-8748"},{"type":"electronic","value":"1526-4610"}],"subject":[],"published":{"date-parts":[[2025,8,27]]},"assertion":[{"value":"2025-01-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}